ArticleMycoses2026
Reduced Activity of Triazole Antifungal Agents Against Aspergillus tubingensis From a Global Collection of Genomically-Characterized Aspergillus Section Nigri Clinical Isolates (2020-2023).
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe black moulds comprising Aspergillus section Nigri are clinically important organisms causing aspergillosis and otomycosis; triazole (azole) antifungal agents represent the primary prophylaxis and treatment option for these infections. The cryptic nature of species within section Nigri presents challenges for routine identification methods, yet accurate speciation may reveal important and overlooked trends in species distribution and azole antifungal activity.
methodWe used whole genome sequencing and comparative genomics to speciate 135 clinical A. section Nigri isolates collected worldwide from 2020 to 2023 and broth microdilution susceptibility testing to assess antifungal agent activity.
resultsA. welwitschiae (n = 61; 45.2%) and A. tubingensis (n = 51; 37.8%) were the primary species identified. A. tubingensis accounted for 87.9% (n = 29/33) of isolates producing azole MIC values above the CLSI-established A. niger epidemiological cutoff values (ECV). All azoles displayed high activity (≥ 93.7% wildtype [WT]) against A. welwitschiae and A. niger isolates; A. tubingensis isolates were broadly inhibited by posaconazole (100% WT). The frequency of A. tubingensis isolates with NWT phenotypes against ≥ 2 azoles and the modal MIC values for most agents increased over time; azole-NWT isolates were present across all regions. Comparisons of protein sequences of CYP51A and CYP51B, the molecular target of azole activity, revealed unique residues in A. tubingensis. However, most azole-NWT isolates across species lacked unique CYP51A/B alterations, suggesting mechanisms outside target site modification influence elevated azole MIC values in this section.
conclusionsOur results demonstrate the utility of speciating clinically relevant organism groups to better understand the dynamics of antifungal agent activity and species distributions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.